Player Avatar JoeArizona (43.81) Submitted: 2/18/2013 5:38:25 PM : Outperform Start Price: $4.74 EXEL Score: -90.46

Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, EXEL will take off.

Featured Broker Partners